ClinicalTrials.gg
RecruitingNCT06553950Updated Aug 16, 2024

Mandibular Splint vs Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders

An interventional study of Botox injection and Mandibular stabilization splint in Mandibular Splint, Botox and Lateral Pterygoid, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders — 3 open to participants now, 3 under way, none of them phase 3. botulinum toxin type A · Temporomandibular Joint Disorders.

Planned enrollment
7th of 11
33 · median 72
Started
2024
with 2 others
No phase
5 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Cairo University

Among the 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders, this one is the 7th largest by planned enrollment, is one of 3 that started in 2024, is one of 5 with no phase, and was the 6th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

3 of the 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders, or all of them as a file.
02

Study summary

The study aims to compere mandibular splint versus botox injection in lateral pterygoid on cervical muscle activity in patients with temporomandibular disorders

Read the detailed description

Temporomandibular disorders (TMD) are common chronic musculoskeletal pain conditions among orofacial pain, consisting of a group of conditions associated with pain and dysfunction of the temporomandibular joint (TMJ) and masticatory muscles. Temporomandibular joint displacement, also known as internal disc derangement, is an abnormal relationship between the articular disc, the mandibular condyle, and the mandibular fossa. The most frequent displacement of the disc is anterior to the mandibular condyle however, in rare cases it can be posteriorly.

Occlusal splint treatment is generally considered to be a basic treatment for Temporomandibular disorders. It could promote correction of the vertical dimension, maxillo-mandibular realignment, temporomandibular joint repositioning and cognitive awareness. Although various splints are currently available, the most used are stabilization splints and anterior repositioning splints.

Injection of BTX-A in LP muscle, considering the different methods, frequencies and injection dosages used in different studies, would decrease the clicks and other TMJ-related disorders such as pain, hyperactivity, and dysfunction. Based on the present review, most studies about the injection of botulinum toxin in LP muscle reported cases or were done as quasi-experimental studies.

03

Conditions studied

  • Mandibular Splint
  • Botox
  • Lateral Pterygoid
  • Cervical Muscle Activity
  • Temporomandibular Disorders
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 18-40 years old.
  • Both sexes.
  • Duration of the disease is more than 3 months.
  • Anterior mandibular disc displacement with reduction will be included.
  • Unilateral anterior mandibular displacement with reduction grade 2\&3 (Wilkes) will be included.
  • Patients with cervical muscles spasm and trigger points (upper trapezius\& sternocleidomastoid) will be included.
  • Patients with sufficient cognitive abilities that enables them to understand and follow instructions.

Exclusion criteria

Exclusion Criteria:

  • Neurological or musculoskeletal diseases that affect cervical spine other than mandibular disc displacement (eg: cervical spondylosis, spondylolisthesis, and cervical disc injuries)
  • Bilateral anterior mandibular disc displacement patients.
  • Musculoskeletal disorders such as severe arthritis, cervical spine surgery or contractures of fixed deformity, leg length discrepancy.
  • women during pregnancy and lactation.
  • Patients with known to any component of the drug (especially hypersensitivity to human albumin).
  • Patients with infection or inflammation of the area where the toxin injections are planned, in patients with musculoskeletal conduction disorders, in primary muscular disorders (muscular dystrophy, neuromyopathy, congenital myopathies, myotonic disorders, mitochondrial myopathy and unspecified or other primary muscle disorders).
  • Patients being treated with aminoglycoside antibiotics, ciclosporin, D-penicillamine, tubocurarine, pancuronium, gallamine, succinylcholine, chloroquine, or hydroxychloroquine.
  • History of cervical spine surgery.
  • History of trauma or fractures in cervical spine.
  • Signs of cervical radiculopathy or myelopathy.
  • Vascular syndrome such as vertebrobasilar insufficiency.
  • Signs of serious pathology ( e.g., , inflammatory disorders, infection).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Botox injection group

    Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants, and nonsteroidal anti-inflammatory drugs. A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle

    Drug: Botox injection

  • Experimental
    Mandibular stabilization splint group

    Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.

    Drug: Mandibular stabilization splint

  • Active comparator
    Control group

    Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.

    Drug: Muscle relaxant

Interventions

  • DrugBotulinum toxin type AStudies of Botulinum toxin type ABotulinum toxin type A pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs. A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle.

  • DrugMandibular stabilization splint

    Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.

  • DrugMuscle relaxant

    Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.

06

What researchers measure

Primary outcomes

  1. Muscle activity of upper trapizieus and sternocleidomastoid

    Muscle activity of upper trapizieus and sternocleidomastoid will be recorded before and after injection for 3 months by neurosoft Electromyography

    Time frame: After injection for 3 months.

Secondary outcomes

  1. Amplitude of muscle activity

    Amplitude of muscle activity will be recorded before and after injection for 3 months by neurosoft Electromyography.

    Time frame: After injection for 3 months.

  2. Root mean square of muscle activity

    Root mean square of muscle activity will be recorded before and after injection for 3 months by neurosoft Electromyography.

    Time frame: After injection for 3 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Feb 2025, 5 months after the start.

Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 5 months is below that.

Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 14, 2024
StartActual
Aug 14, 2024
Primary completionEst.
Feb 1, 2025
CompletionEst.
Feb 1, 2025
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06553950
Lead sponsor
Cairo University
Responsible party
Kerolos Ghobrial Goda Abd-El Malak (Resident of Physical Therapy , Faculty of Physical Therapy ,Cairo University, Cairo, Egypt., Cairo University) — Principal investigator
First posted
Aug 14, 2024
Start date
Aug 14, 2024
Primary completion
Feb 1, 2025 (estimated)
Completion
Feb 1, 2025 (estimated)
Last update
Aug 16, 2024

Study contacts

Kerolos G Abd-El Malak, MBBCH
Contact
Kerols.ghobreal@deraya.edu.eg
00201276145151

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion